DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business. Second Quarter 2022 Financial Highlights Cash position Cash was $265.


Previous articlePT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch, and The Value of Preparation
Next articleAlgernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position